NOVEL ANTITUMOR AGENTS CI-920, PD 113, 270 AND PD 113, 271: I. TAXONOMY, FERMENTATION AND BIOLOGICAL PROPERTIES

CI-920 (PD 110, 161) and two analogues (PD 113, 270 and PD 113, 271) are novel antitumor compounds produced by a new actinomycete characterized as Streptomyces pulveraceus subsp. fostreus ATCC 31906. The antitumor compounds are predominantly produced during the stationary (idiophase) growth phase of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antibiotics 1983, Vol.36(12), pp.1595-1600
Main Authors: TUNAC, J. B., GRAHAM, B. D., DOBSON, W. E.
Format: Article
Language:English
Subjects:
Alkenes - isolation & purification
Alkenes - toxicity
Animals
antibiotic CI-920
antibiotic PD 113,270
antibiotic PD 113,271
Antibiotics
Antibiotics, Antineoplastic - isolation & purification
Antineoplastic agents
antitumor antibiotics
Biological and medical sciences
Biotechnology
Drug Evaluation, Preclinical
Fermentation
Fundamental and applied biological sciences. Psychology
General aspects
Health. Pharmaceutical industry
Industrial applications and implications. Economical aspects
Leukemia L1210 - drug therapy
Leukemia P388 - drug therapy
Medical sciences
Mice
Microbial Sensitivity Tests
Pharmacology. Drug treatments
Polyenes
Production of active biomolecules
Pyrones
Streptomyces - growth & development
Streptomyces pulveraceus
Streptomyces pulveraceus fostreus
Structure-Activity Relationship
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CI-920 (PD 110, 161) and two analogues (PD 113, 270 and PD 113, 271) are novel antitumor compounds produced by a new actinomycete characterized as Streptomyces pulveraceus subsp. fostreus ATCC 31906. The antitumor compounds are predominantly produced during the stationary (idiophase) growth phase of the organism. CI-920 is active versus the murine P388 lymphocytic and L1210 lymphoid leukemia with T/C values of 246 and 207, respectively. This compound has no significant antimicrobial activity.
ISSN:0021-8820
1881-1469
DOI:10.7164/antibiotics.36.1595